Pharmaceutical companies have invested heavily in drugs, such as ulotaront, that target this receptor. However, recent clinical trials for ulotaront did not meet expectations, leaving researchers asking if genetic differences between patients are to blame.
4 Likes
Thanks for posting @everhopeful
1 Like
Thus not being South Asian Ulotaront may work for me…
APs in general work for one and not another in the field.
I’d like a genetic screening to see which ones work for me and which do not, is this avaialble yet?
Copilot says this test isn’t available yet. No dosing considerstions can be made from a genetic test for cobenfy or ulotaront at present with the current genomic tests privately or nhs wise.
1 Like
Chatting with copilot it says that this genetic marker is rare and wouldn’t have been the deciding factor in phase 3 fda failure.
1 Like
Interesting. Thanks.
1 Like